KURA

6.9455.51%
TR

Thomas Robert Malley

Independent Director

Mr. Thomas Robert Malley, CFA served as Member of Advisory Committee of BeiGene, Ltd. until January 22, 2024. He served as an Independent Non-Executive Director at BeiGene, Ltd. since January 2016 until January 22, 2024. Mr. Malley has served on the Board of Directors of LincSwitch Therapeutics, Inc., a privately-held company, since September 2024. He joined the BeiGene, Ltd. in January 2016. He has served as President of Mossrock Capital, LLC. since May 2007. Mr. Malley served as Portfolio Manager and Securities Analyst at Janus Capital Management LLC. From 1991 to 1998, he served as an Equity Analyst for Janus covering, among others, healthcare and biotechnology stocks, telecommunications, gaming and lodging and housing stocks. From April 1991 to May 2007, he served in various roles at Janus Mutual Funds. He joined Janus Aspen Global in April 1991 as a Research Analyst and focused on the life sciences area as well as on large capitalization healthcare and pharmaceutical companies. He has experience as a Consultant for a computer firm. He served as a Portfolio Manager and Securities Analyst at Janus Investment Fund - Janus Global Life Sciences Fund from January 1999 to May 2007. He served as an Executive Vice President at Janus Aspen Global Life Sciences Portfolio since December 1999 and also served as its Co-Portfolio Manager. He served as an Independent Director of OvaScience, Inc. since October 2012 until June 12, 2017. Mr. Malley has been an Independent Director at Kura Oncology, Inc. since October 13, 2015. He served as a Director at Puma Biotechnology, Inc. from October 4, 2011 to September 11, 2015. He served as a Director of Cougar Biotechnology Inc. from June 12, 2007 to 2009, until its acquisition by Johnson and Johnson and served as Director of Synageva BioPharma Corp. from October 2006 to June 22, 2015, until its acquisition by Alexion Pharmaceuticals, Inc. He has been an Independent Director of Kiniksa Pharmaceuticals International, plc (formerly known as Kiniksa Pharmaceuticals, Ltd.) since December 2016. Mr. Malley holds a B.S. in Molecular Biology from the Stanford University in 1991. He is a Chartered Financial Analyst.

Positions